TuHURA Biosciences, Inc./NV — Director's Dealing 2021

Sep 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kintara Therapeutics, Inc. (KTRA)
CIK: 0001498382
Period of Report: 2021-09-22

Reporting Person: Murphy Keith (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-22	Options (Right to Buy)	$1.24	A	100000	Acquired	2031-09-22	Common Stock (100000)	Direct

Footnotes

F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.